Skip to main content
SpringerLink
Log in

Angiogenesis inhibition in renal cell cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Several targets have been identified for the therapy of metastatic renal cell carcinoma (RCC). The recognition of hypoxia-inducible factor-α signaling in the pathogenesis of clear-cell RCC has led to widespread study of angiogenesis inhibitors. Understanding this molecular pathogenesis of RCC led to a rapid evolvement of new systemic therapies, with seven targeted therapies approved and several more agents in late-stage clinical development. Due to the results of the currently used targeted therapies, the progression-free survival could be prolonged and the overall survival in sequential therapy can reach up to 40 months. The development of validated guidelines for sequential treatment or combination of targeted therapy remains a current challenge.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Escudier B, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl. 7):vii65–71.

    Google Scholar 

  2. Kaelin WG, Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2(9):673–82.

    Article  CAS  PubMed  Google Scholar 

  3. Kondo K, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel–Lindau protein. Cancer Cell. 2002;1(3):237–46.

    Article  CAS  PubMed  Google Scholar 

  4. Cho D, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007;5(6):379–85.

    Article  CAS  PubMed  Google Scholar 

  5. Toi M, et al. Clinical significance of the determination of angiogenic factors. Eur J Cancer. 1996;32A(14):2513–9.

    Article  CAS  PubMed  Google Scholar 

  6. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol. 1995;22(1):42–60.

    CAS  PubMed  Google Scholar 

  7. Bellmunt J, et al. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int. 2009;104(1):10–8.

    Article  CAS  PubMed  Google Scholar 

  8. Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  9. Motzer RJ, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Escudier B, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–50.

    Article  CAS  PubMed  Google Scholar 

  11. Motzer RJ, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.

    Article  CAS  PubMed  Google Scholar 

  12. Escudier B, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32(14):1412–8.

    Article  CAS  PubMed  Google Scholar 

  13. Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    Article  CAS  PubMed  Google Scholar 

  14. Poprach A, et al. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urol Oncol. 2014;32(4):488–95.

    Article  CAS  PubMed  Google Scholar 

  15. Herrmann E, et al. Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology. 2008;74(3–4):216–22.

    Article  CAS  PubMed  Google Scholar 

  16. Gonzalez Larriba JL, et al. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 2012;31(Suppl. 1):S11–7.

    Article  PubMed  Google Scholar 

  17. Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  18. Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    Article  CAS  PubMed  Google Scholar 

  19. Rini BI, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.

    Article  CAS  PubMed  Google Scholar 

  20. Escudier B, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(8):1280–9.

    Article  CAS  PubMed  Google Scholar 

  21. Calvo E, Grunwald V, Bellmunt J. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. Eur J Cancer. 2014;50(7):1321–1329.

    Article  CAS  PubMed  Google Scholar 

  22. Funakoshi T, Lee CH, Hsieh JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev. 2014;40(4):533–47.

    Article  CAS  PubMed  Google Scholar 

  23. Bierer S, et al. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma. Oncol Rep. 2008;20(4):721–5.

    CAS  PubMed  Google Scholar 

  24. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol. 2009;20(5):966–7. Author reply 967.

  25. Schmidinger M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117(3):534–44.

    Article  PubMed  Google Scholar 

  26. Asemissen AM, Brossart P. Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother. 2009;58(7):1169–74.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The author declares that there are no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. Department of Urology, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria

    Nicolai Leonhartsberger MD

Authors
  1. Nicolai Leonhartsberger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolai Leonhartsberger MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leonhartsberger, N. Angiogenesis inhibition in renal cell cancer. memo 7, 211–213 (2014). https://doi.org/10.1007/s12254-014-0160-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0160-x

Keywords

Search

Navigation